Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Cited by (1,006)

Items 301–400 of 1,006

1. Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents
   Carmel Jo Pezaro, Aurelius Gabriel Omlin, Amelia Altavilla, David Lorente, Roberta Ferraldeschi, Diletta Bianchini, David Paul Dearnaley, Chris C. Parker, Johann Sebastian De Bono, Gerhardt Attard · 2013 · European Urology
2. Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells
   Luigi Ippolito, Alberto Marini, Lorenzo Cavallini, Andrea Morandi, Laura Pietrovito, Gianfranco Pintus, Elisa Giannoni, Thomas H. Schrader, Martin Puhr, Paola Chiarugi et al. · 2016 · Oncotarget
3. Sipuleucel-T
   Celestia S. Higano, Eric Jay Small, Paul F. Schellhammer, Uma Yasothan, Steven I. Gubernick, Peter N. Kirkpatrick, Philip W. Kantoff · 2010 · Nature Reviews Drug Discovery
4. Docetaxel-based combination therapy for castration-resistant prostate cancer
   Matthew D. Galsky, Nicholas J. Vogelzang · 2010 · Annals of Oncology
5. The establishment of two paclitaxel‐resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines
   Masashi Takeda, Atsushi Mizokami, Kiminori Mamiya, You Qiang Li, Jian Zhang, Evan T. Keller, Mikio Namiki · 2007 · The Prostate
6. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment
   Madhav Prasad Yadav, Sanjana Ballal, Madhavi Tripathi, Nishikant Avinash Damle, Ranjit Kumar Sahoo, Amlesh Seth, Chandrasekhar Bal · 2016 · European Journal of Nuclear Medicine and Molecular Imaging
7. Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics
   R BOARD, Gordon C. Jayson · 2005 · Drug Resistance Updates
8. The evolving biology and treatment of prostate cancer
   Russell S. Taichman, Robert D. Loberg, Rohit Mehra, Kenneth J. Pienta · 2007 · Journal of Clinical Investigation
9. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)
   Deborah Bradley, Dana E. Rathkopf, Rodney L. Dunn, Walter Michael Stadler, Glenn Liu, David Carl Smith, Роберто Пили, James A. Zwiebel, Howard I. Scher, Maha Hussain · 2009 · Cancer
10. A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer
    Samuel J. Vidal, Verónica Rodríguez-Bravo, S. Aidan Quinn, Ruth Rodriguez Barrueco, Amaia Lujambio, Estrelania S. Williams, Xiaochen Sun, Janis de la Iglesia-Vicente, Albert Lee, Ben Readhead et al. · 2015 · Cancer Cell
11. Prostate cancer: ESMO Consensus Conference Guidelines 2012
    Alan Horwich, Jonas Hugosson, Theo M. de Reijke, Thomas Wiegel, Karim S. Fizazi, Vesa V Kataja, Chris C. Parker, Joaquim Bellmunt B, Dominik Berthold, Anna Bill‐Axelson et al. · 2013 · Annals of Oncology
12. Phase I Trial of the Prostate-Specific Membrane Antigen–Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer
    Galsky, Matthew D., Eisenberger, Mario, Moore-Cooper, Sandra, Kelly, W. Kevin, Slovin, Susan F., DeLaCruz, Anthony, Lee, Yih, Webb, Iain J., Scher, Howard I. · 2008 · Journal of Clinical Oncology
13. Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
    Yangmin M. Ning, James L. Gulley, Philip Martin Arlen, Sukyung Woo, Seth M. Steinberg, John J. Wright, Howard L. Parnes, Jane B. Trepel, Min-Jung Lee, Yeong Sang Kim et al. · 2010 · Journal of Clinical Oncology
14. Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel
    John M. Fitzpatrick, Joaquim Bellmunt B, Karim S. Fizazi, Axel Heidenreich, Cora Nanette Sternberg, Bertrand F. TOMBAL, Antonio Alcaraz, Amit K. Bahl, Sergio Bracarda A, Giuseppe Di Lorenzo et al. · 2014 · European Journal of Cancer
15. The changing therapeutic landscape of castration-resistant prostate cancer
    Timothy Anthony Yap, Andrea Zivi, Aurelius Gabriel Omlin, Johann Sebastian De Bono · 2011 · Nature Reviews Clinical Oncology
16. Overcoming docetaxel resistance in prostate cancer: a perspective review
    Clara Hwang · 2012 · Therapeutic Advances in Medical Oncology
17. Role of chemotherapy in prostate cancer
    Jeanny B. Aragon‐Ching, Rita Nader, Joelle El-Amm · 2017 · Asian Journal of Andrology
18. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial
    Aude Fléchon, Damien Pouessel, Céline Ferlay, David Pérol, Philippe Beuzeboc, Gwénaëlle Gravis, Florence Joly, Stéphane Marie. Oudard, G. Deplanque, Sylvie Zanetta et al. · 2011 · Annals of Oncology
19. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer
    Fizazi, Karim, Massard, Christophe, Smith, Matthew, Rader, Michael, Brown, Janet, Milecki, Piotr, Shore, Neal, Oudard, Stephane, Karsh, Lawrence, Carducci, Michael et al. · 2015 · European Urology
20. Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancer
    Scott T. Tagawa, Himisha Beltran, Shankar Vallabhajosula, Stanley J. Goldsmith, Joseph R. Osborne, Dan Matulich, Kristen Petrillo, Sarojben Parmar, David M. Nanus, Neil Harrison Bander · 2010 · Cancer
21. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials
    Robert J. van Soest, Arnoud J. Templeton, Francisco Vera-Badillo, Florence Mercier, Guru Sonpavde, Eitan Amir, Bertrand F. TOMBAL, Mark Andrew Rosenthal, Mario A. Eisenberger, Ian F. Tannock et al. · 2014 · Annals of Oncology
22. The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study
    Hakim Mahammedi, Eloïse Planchat, Mélanie Pouget, Xavier Durando, Hervé Curé, Laurent Guy, Isabelle Van-Praagh, Laurent Savareux, Marc Atger, Mathilde Bayet‐Robert et al. · 2016 · Oncology
23. Drug discovery in advanced prostate cancer: translating biology into therapy
    Timothy Anthony Yap, Alan David Smith, Roberta Ferraldeschi, Bissan Al‐Lazikani, Paul Workman, Johann Sebastian De Bono · 2016 · Nature Reviews Drug Discovery
24. Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy
    Anna Katharina Seitz, Isabel Rauscher, Bernhard Haller, Markus Kroenke, S. Luther, Matthias Michael Heck, Thomas D Horn, Jürgen E. Gschwend, Markus Schwaiger, Matthias J. Eiber et al. · 2017 · European Journal of Nuclear Medicine and Molecular Imaging
25. Androgen deprivation of prostate cancer: Leading to a therapeutic dead end
    A. Katzenwadel, Philipp Wolf · 2015 · Cancer Letters
26. Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression
    Ravi Amrit Madan, James L. Gulley, Tito Fojo, William L. Dahut · 2010 · The Oncologist
27. Managing bone metastases and reducing skeletal related events in prostate cancer
    Benjamin Adam Gartrell, Fred Saad C · 2014 · Nature Reviews Clinical Oncology
28. Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)
    Francolini, Giulio, Allegra, Andrea Gaetano, Detti, Beatrice, Di Cataldo, Vanessa, Caini, Saverio, Bruni, Alessio, Ingrosso, Gianluca, D'Angelillo, Rolando Maria, Alitto, Anna Rita, Augugliaro, Matteo et al. · 2023 · Journal of Clinical Oncology
29. Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms
    Agnès Tran, Vincent Jullien, Jérôme Alexandre, Elisabeth Rey, F. Rabillon, V. Girre, Veronique C Dieras, Gérard Pons, François Goldwasser, Jean‐Marc Tréluyer · 2006 · Clinical Pharmacology & Therapeutics
30. ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel
    Tristan M. Sissung, Caitlin E. Baum, John F. Deeken, Douglas K. Price, Jeanny B. Aragon‐Ching, Seth M. Steinberg, William L. Dahut, Alex Sparreboom, William Douglas Figg · 2008 · Clinical Cancer Research
31. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer
    Jeanny B. Aragon‐Ching · 2007 · Frontiers in bioscience
32. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials
    Arnoud J. Templeton, Francisco Vera-Badillo, L. Wang, Mirna Attalla, Paulo De Gouveia, Raya Leibowitz‐Amit, Jennifer Jane Knox, Malcolm J. Moore, Srikala S. Sridhar, Anthony Michael Joshua et al. · 2013 · Annals of Oncology
33. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
    Guru Sonpavde, Phillip Periman, Dirk M. Bernold, Douglas Jay Weckstein, Mark T. Fleming, Matthew D. Galsky, William R. Berry, F. Zhan, Kristi A. Boehm, Lina Asmar et al. · 2009 · Annals of Oncology
34. Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment
    Srikala S. Sridhar, Stephen J. Freedland, Martin Edwin Gleave, Celestia S. Higano, Peter Mulders, Chris C. Parker, Oliver A. Sartor, Fred Saad C · 2013 · European Urology
35. Ex vivo culture of human prostate tissue and drug development
    Margaret M. Centenera, Ganesh V. Raj, Karen E. Knudsen, Wayne D. Tilley, Lisa M. Butler · 2013 · Nature Reviews Urology
36. The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer
    Michael Thomas Schweizer, Xian C. Zhou, Hao Wang, Sunakshi Bassi, Michael Anthony Carducci, Mario A. Eisenberger, Emmanuel S. Antonarakis · 2014 · European Urology
37. Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance
    Daniel James Crona, Young E. Whang · 2017 · Cancers
38. Taxane Mechanisms of Action: Potential Implications for Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer
    John M. Fitzpatrick, Ronald de Wit · 2013 · European Urology
39. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer
    H-M Lin, Lesley E. Castillo, Kate Lynette Mahon, Keng Hoong Chiam, Byeong Yeop Lee, Quoc Anh Nguyen, Michael Joseph Boyer, Martin R. Stockler, Nick Pavlakis, Gavin M. Marx et al. · 2014 · British Journal of Cancer
40. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E
    Claudia Andrieu, David Taïeb, Virginie Baylot, Susan Ettinger, Philippe Soubeyran, Aurélie de Thonel, Colleen C. Nelson, Carmen Garrido, Alan So, Ladan Fazli et al. · 2010 · Oncogene
41. Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials
    Andrew Gdowski, Amalendu Prakash Ranjan, Jamboor K. Vishwanatha · 2017 · Journal of Experimental & Clinical Cancer Research
42. Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic
    Christopher J. D. Wallis, Giacomo Novara, Laura Marandino, Axel Bex, Ashish M. Kamat, Robert Jeffrey Karnes, Todd Matthew Morgan, Nicolas Mottet, Silke Gillessen, Alberto Bossi et al. · 2020 · European Urology
43. PAMAM Dendrimers Mediate siRNA Delivery to Target Hsp27 and Produce Potent Antiproliferative Effects on Prostate Cancer Cells
    Xiaoxuan Liu, Palma Rocchi, Fanqi Qu, Shu‐quan Zheng, Zicai Liang, Martin Edwin Gleave, Juan Iovanna, Ling Peng · 2009 · ChemMedChem
44. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel‐induced leukopenia
    Kazuma Kiyotani, Taisei Mushiroda, Michiaki Kubo, Hitoshi Zembutsu, Yuichi Sugiyama, Yusuke Nakamura · 2008 · Cancer Science
45. Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
    Farshid Dayyani, Gary E. Gallick, Christopher J. Logothetis, Paul Gettys Corn · 2011 · JNCI Journal of the National Cancer Institute
46. Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling
    Lisa J. Frederiksen, Richard Sullivan, Lori Maxwell, Shannyn K. Macdonald-Goodfellow, MICHAEL A. ADAMS, Brian M. Bennett, David Robert Siemens, Charles H. Graham · 2007 · Clinical Cancer Research
47. Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer
    Antoîne Italiano, Cécile Ortholan, Stéphane Marie. Oudard, Damien Pouessel, Gwénaëlle Gravis, Philippe Beuzeboc, Emmanuelle Bompas, Aude Fléchon, Florence Joly, Jean-­Marc Ferrero et al. · 2008 · European Urology
48. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease
    Alfredo Berruti, Alessandra Mosca, Marco Tucci, Carlo Terrone, MIRELLA TORTA, Roberto Tarabuzzi, Lucianna Maria Russo, Cecilia Maria Cracco, Enrico Bollito, Roberto Mario Scarpa et al. · 2005 · Endocrine Related Cancer
49. Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
    Fred Saad C, Sebastién J. Hotte, Scott A. North, Bernhard J. Eigl, Kim Chi, Piotr Czaykowski, Lori Anne Wood, Michaël Pollak, Scott R. Berry, Jean‐Baptiste Lattouf et al. · 2011 · Clinical Cancer Research
50. Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
    Dominika Ewelina Butler, Christopher Richard Marlein, Hannah F. Walker, Fiona M. Frame, Vincent M. Mann, Matthew S. Simms, Barry R. Davies, Anne T. Collins, Norman J. Maitland · 2017 · Oncotarget
51. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer
    James Andrew Eastham, Glenn Heller, Susan Halabi, J. Paul Monk, Himisha Beltran, Martin Edwin Gleave, Christopher P. Evans, Steven K. Clinton, Russell Zelig Szmulewitz, Jonathan Coleman et al. · 2020 · Journal of Clinical Oncology
52. Clinical Outcomes of 177 Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy
    Thomas W. Barber, Aviral Singh, Harshad Kulkarni, Karin Niepsch, Baki Billah, Richard Paul Baum · 2019 · Journal of Nuclear Medicine
53. The treatment landscape of metastatic prostate cancer
    Yasutaka Yamada, Himisha Beltran · 2021 · Cancer Letters
54. Prostate Cancer Overview
    Mary Weinstein Dunn, Meredith Wallace Kazer · 2011 · Seminars in Oncology Nursing
55. The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
    Daniel Castellano, Juan Manuel Sepúlveda-Sánchez, Ignacio García-Escobar, Alfredo Rodríguez-Antolín, Anna Sundlöv, H. Cortés-Funes · 2011 · The Oncologist
56. Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer
    Chen-Yun Yeh, Jong‐Kai Hsiao, Yi‐Ping Wang, Chun-Hsin Lan, Han‐Chung Wu · 2016 · Biomaterials
57. Landmarks in prostate cancer
    Niranjan Jude Sathianathen, Badrinath R. Konety, Juanita Mary Crook, Fred Saad C, Nathan Lawrentschuk · 2018 · Nature Reviews Urology
58. Arachidonic Acid Pathway Members PLA2G7, HPGD, EPHX2, and CYP4F8 Identified as Putative Novel Therapeutic Targets in Prostate Cancer
    Paula Vainio, Santosh Gupta, Kirsi Ketola, Tuomas K. Mirtti, John-Patrick Mpindi, Pekka J. Kohonen, Vidal Fey, Merja Perälä, Frank P. Smit, Gerald W.C.T Verhaegh et al. · 2011 · American Journal Of Pathology
59. Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step Backwards
    Howard I. Scher, Michael J. Morris, William Kevin Kelly, Lawrence Howard Schwartz, Glenn Heller · 2005 · Clinical Cancer Research
60. Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer
    Dana E. Rathkopf, Howard I. Scher · 2013 · The Cancer Journal
61. Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer
    Mu‐Yi Hua, Hung‐Wei Yang, Cheng‐Keng Chuang, Rung‐Ywan Tsai, Wen-Jauh Chen, Kun‐Lung Chuang, Ying‐Hsu Chang, Heng‐Chang Chuang, See‐Tong Pang · 2010 · Biomaterials
62. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival
    Andrew J. Armstrong, Ian F. Tannock, Ronald de Wit, Daniel J. George, Mario A. Eisenberger, Susan Halabi · 2009 · European Journal of Cancer
63. Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study
    Giuseppe Di Lorenzo, William Douglas Figg, Sophie D. Fosså, Vincenzo G. Mirone, Riccardo Autorino B, Nicola Longo, Ciro Imbimbo, Sisto Perdonà, Antonio Giordano, Mario Giuliano et al. · 2008 · European Urology
64. Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer
    Andrea Borghese Apolo, Neeta D. Pandit-Taskar, Michael J. Morris · 2008 · Journal of Nuclear Medicine
65. Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
    Alexander William Wyatt, Martin Edwin Gleave · 2015 · EMBO Molecular Medicine
66. The role of GATA2 in lethal prostate cancer aggressiveness
    Verónica Rodríguez-Bravo, Marc Carceles‐Cordon, Yujin Hoshida, Carlos Cordon‐Cardo, Matthew D. Galsky, Josep M. Domingo Domenech · 2016 · Nature Reviews Urology
67. Androgen receptor splice variants and prostate cancer: From bench to bedside
    Kristine M. Wadosky, Shahriar Koochekpour · 2017 · Oncotarget
68. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel
    Lauren C. Harshman, Yu‐Hui Chen, Glenn Liu, Michael Anthony Carducci, David Frazier Jarrard, Robert Dreicer, Noah M. Hahn, Jorge Alberto Garcia, Maha Hussain, Daniel H. Shevrin et al. · 2017 · Journal of Clinical Oncology
69. Radium-223 mechanism of action: implications for use in treatment combinations
    Michael J. Morris, Eva Corey, Theresa A. Guise, James L. Gulley, William Kevin Kelly, David I. Quinn, Arne Scholz, George Sgouros · 2019 · Nature Reviews Urology
70. Phase I Trial of Intravesical Docetaxel in the Management of Superficial Bladder Cancer Refractory to Standard Intravesical Therapy
    James M. McKiernan, Puneet Masson, Alana M Murphy, Manlio A. Goetzl, Carl A. Olsson, Daniel Peter Petrylak, Manisha Desai, Mitchell C. Benson · 2006 · Journal of Clinical Oncology
71. miRNA-708 Control of CD44+ Prostate Cancer–Initiating Cells
    Sharanjot Saini, Shahana Majid, Varahram Shahryari, Sumit Arora, Soichiro Yamamura, Inik Chang, Mohd Saif Zaman, Guoren Deng, Yuichiro Tanaka, Rajvir Dahiya · 2012 · Cancer Research
72. The PIM1 Kinase Is a Critical Component of a Survival Pathway Activated by Docetaxel and Promotes Survival of Docetaxel-treated Prostate Cancer Cells
    Marina Zemskova, Eva Sahakian, Svetlana Bashkirova, Michael B. Lilly · 2008 · Journal of Biological Chemistry
73. Multicenter Phase II Study of Combined Neoadjuvant Docetaxel and Hormone Therapy Before Radical Prostatectomy for Patients With High Risk Localized Prostate Cancer
    Kim N. Chi, Joseph L. Chin, Eric Winquist, Laurence H. Klotz, Fred Saad C, Martin Edwin Gleave · 2008 · The Journal of Urology
74. EXPRESSION OF CONCERN: Functional p53 determines docetaxel sensitivity in prostate cancer cells
    Chengfei Liu, Yezi Zhu, Wei Lou, Nagalakshmi Nadiminty, Xinbin Chen, Qinghua Zhou, Xu Shi, Ralph Devere White, Allen C. Gao · 2012 · The Prostate · Retracted
75. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles
    David T. Hoang, Kenneth A. Iczkowski, Deepak Kilari, William A. See, Marja T. Nevalainen · 2016 · Oncotarget
76. Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel
    Susan Halabi, Sandipan Dutta, Catherine M. Tangen, Mark Andrew Rosenthal, Daniel Peter Petrylak, Ian Murchie Thompson, Kim N. Chi, John C. Araujo, Christopher J. Logothetis, David I. Quinn et al. · 2018 · Journal of Clinical Oncology
77. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018
    William Thomas Lowrance, Mohammad Hassan Murad, William K. Oh, David Frazier Jarrard, Matthew Jason Resnick, Michael S. Cookson · 2018 · The Journal of Urology
78. RETRACTED: Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells
    Chapla Agarwal, Alpna Tyagi, Manjinder Kaur, Rajesh Agarwal · 2007 · Carcinogenesis · Retracted
79. No improvement noted in overall or cause‐specific survival for men presenting with metastatic prostate cancer over a 20‐year period
    Jennifer N. Wu, Kari M. Fish, Christopher P. Evans, Ralph Devere White, Marc Dall’Era · 2013 · Cancer
80. ERG induces taxane resistance in castration-resistant prostate cancer
    Giuseppe Galletti, Alexandre Matov, Himisha Beltran, Jacqueline Fontugne, Juan Miguel Mosquera, Cynthia Cheung, Theresa Y. MacDonald, Matthew S. Sung, Sandra A O'Toole, James G. Kench et al. · 2014 · Nature Communications
81. Novel Biomarkers for Prostate Cancer Including Noncoding Transcripts
    Tammy L Romanuik, Takeshi Ueda, Nhu Le, Simon Haile, Theresa M.K. Yong, Thomas A. Thomson, Robert L. Vessella, Marianne D. Sadar · 2009 · American Journal Of Pathology
82. MBP-1 Upregulates miR-29b, Which Represses Mcl-1, Collagens, and Matrix Metalloproteinase-2 in Prostate Cancer Cells
    Robert Steele, Justin L. Mott, Ratna B. Ray · 2010 · Genes & Cancer
83. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
    Cora Nanette Sternberg, Herlinde Dumez, Hendrik Van Poppel, Iwona Skoneczna, Avishay Sella, Gedske Daugaard, Thierry Gil, J. Graham, P. Carpentier, Fabio Calabrò et al. · 2009 · Annals of Oncology
84. Targeting bone metastases in prostate cancer: improving clinical outcome
    Jean‐Jacques Body, Sandra Casimiro, Luís Costa · 2015 · Nature Reviews Urology
85. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial
    Fred Saad C, Karim S. Fizazi, Viorel Jinga, Eleni Efstathiou, Peter C.C. Fong, Lowell L. Hart, Robert J. Jones, Ray McDermott, Manfred Peter Wirth, Kazuhiro Suzuki et al. · 2015 · The Lancet Oncology
86. In vivo Knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors
    Robert Snoek, Helen Cheng, Katia Margiotti, Latif A. Wafa, Charmaine A. Wong, Erica Chan Wong, Ladan Fazli, Colleen C. Nelson, Martin Edwin Gleave, Paul S. Rennie · 2008 · Clinical Cancer Research
87. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy
    Guru Sonpavde, Gregory R. Pond, William R. Berry, Ronald de Wit, Andrew J. Armstrong, Mario A. Eisenberger, Ian F. Tannock · 2010 · Urologic Oncology Seminars and Original Investigations
88. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role
    Jianping Huang, Caroline Jochéms, Tara Talaie, Austin Anderson, Alessandra Jales, Kwong Yok Tsang, Ravi Amrit Madan, James L. Gulley, Jeffrey Schlom · 2012 · Blood
89. The role of epithelial–mesenchymal transition drivers ZEB 1 and ZEB 2 in mediating docetaxel‐resistant prostate cancer
    Karen Hanrahan, Amanda O’Neill, Maria Prencipe, Jane Bugler, Lisa Murphy, Aurélie Fabre, Martin Puhr, Zoran Čulig, Keefe Murphy, R. William G. Watson · 2017 · Molecular Oncology
90. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
    Stefanie Hammer, Urs B. Hagemann, Sabine Zitzmann-Kolbe, Aasmund Larsen, Christine Ellingsen, Solène Géraudie, Derek Grant, Baard Indrevoll, Roger Smeets, Oliver von Ahsen et al. · 2019 · Clinical Cancer Research
91. Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases
    Ingrid Herr, Jesco Pfitzenmaier · 2006 · The Lancet Oncology
92. Clinical Safety of a Viral Vector Based Prostate Cancer Vaccine Strategy
    Philip Martin Arlen, Lisa Skarupa, Mary P. Pazdur, Mahesh Seetharam, Kwong Yok Tsang, Douglas W. Grosenbach, Jarett L. Feldman, Diane J. Poole, Mary T. Litzinger, Seth M. Steinberg et al. · 2007 · The Journal of Urology
93. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial
    James, Nicholas D, Sydes, Matthew R, Mason, Malcolm D, Clarke, Noel W, Anderson, John, Dearnaley, David P, Dwyer, John, Jovic, Gordana, Ritchie, Alastair WS, Russell, J Martin et al. · 2012 · The Lancet Oncology
94. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer
    Chengfei Liu, Cameron M. Armstrong, Wei Lou, Alan Paul Lombard, Christopher P. Evans, Allen C. Gao · 2016 · Molecular Cancer Therapeutics
95. AKT‐phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1‐MAPK interaction
    Chun‐Wu Pan, Xin Jin, Yu Wei Zhao, Yunqian Pan, Jing Hui Yang, Robert Jeffrey Karnes, Jun Zhang, Liguo Wang, Haojie Huang · 2017 · The EMBO Journal
96. Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells
    Riccardo Cristofani, Marina Montagnani Marelli, M.E. Cicardi, Fabrizio Fontana, Monica Marzagalli, Patrízia Limonta, Angelo Poletti, Roberta Manuela Moretti · 2018 · Cell Death and Disease
97. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
    Julie Nicole Graff, Tomasz M. Beer, Joshi J. Alumkal, Rachel Slottke, William L. Redmond, GEORGE V. THOMAS, Reid F. Thompson, Mary Ann Wood, Yoshinobu Koguchi, Yiyi Chen et al. · 2020 · Journal for ImmunoTherapy of Cancer
98. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults
    Jean‐Pierre Droz, Lodovico Balducci, M. Bolla, Mark Emberton, John M. Fitzpatrick, Steven Joniau, Michael W. Kattan, Silvio Monfardini, Judd W. Moul, Arash Naeim et al. · 2009 · Critical Reviews in Oncology/Hematology
99. Recommandations en Onco-Urologie 2010 : Cancer de la prostate
    Laurent Salomon, D. Azria, C. Bastide, Philippe Beuzeboc, Luc Cormier, François Cornud, David Eiss, Pascal Eschwège, N. Gaschignard, Christophe Hennequin et al. · 2010 · The French Journal of Urology
100. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score
     Nathan I. Cherny, Elisabeth G.E. de Vries, Urania G. Dafni, Elizabeth S. Garrett-Mayer, Shannon E. McKernin, Martine J Piccart, Nicola Jane Latino, Jean-Yves Douillard, Lowell E. Schnipper, Mark R. Somerfield et al. · 2019 · Journal of Clinical Oncology